Synthetic Carbohydrate Vaccines

"Nearly nine million children under 14 years of age die every year from infectious disease. And at least a third of them could be saved if existing vaccines were more widely used, but the rest only if suitable new vaccines were developed...”  - The World Health Organization

Carbohydrate based vaccines are making their way on to the immunization schedules of many countries for various infectious diseases. Many more are in various stages of development. The manufacturing of these polysaccharide conjugate vaccine (PCV) from fermenting bacteria is a difficult and expensive process making these vaccines unaffordable in many developing countries where it is most needed.

“It is common for there to be a lag of up to 15 years between a vaccine’s availability in the developed world and its widespread availability in developing countries and this is unacceptable” - The All-Party Parliamentary Group (APPG)

Carbohydrate-based vaccines have proven highly efficient in the prevention of infectious diseases like pneumonia and meningitis. Based on this, the vaccine group has envisioned the chemical synthesis and biological evaluation of carbohydrates present on Streptococcus pneumoniae, Yersinia pestis,  Chlamydia, Haemophilus influenzae, Leishmania, Neisseria meningitidis  and Clostridium difficile.

Zur Redakteursansicht